Upon workshop completion, the six trainees demonstrated improved haemophilia-specific PT knowledge and were fully familiar with the HJHS and its administration. The latter was assessed in a mini-reliability study. The ‘Train-the-Trainer’ model is a very effective education programme designed to accelerate training in haemophilia PT to meet the rapidly increasing need for haemophilia-specific rehabilitation
services in a very large country such as China. It is anticipated Cabozantinib that physiatrists/physiotherapists at newly established Chinese haemophilia treatment centres will receive training in haemophilia care as a result of this unique programme in the immediate future. “
“Summary. In patients with severe haemophilia and inhibitors, regular this website factor VIII inhibitor bypassing activity (FEIBA) prophylaxis
has been shown to reduce the frequency of bleeding by up to 85% and to improve patient quality of life. FEIBA is well tolerated; the incidence of thrombotic events and of allergic reactions is extremely low. The concept of prophylaxis in haemophilia patients with inhibitors is relatively new and some clinicians may be unsure of how to use FEIBA in this context. These treatment recommendations, based on published evidence plus the collective experience of a group of haematologists (with practical knowledge of managing inhibitor patients with FEIBA prophylaxis), are intended to provide guidance to clinicians considering initiating and maintaining patients on FEIBA prophylaxis with specific focus on practical aspects of patient selection, dosing, monitoring and stop criteria. “
“Atrial fibrillation (AF) is a common health problem in the general population, but data on prevalence or management in patients with haemophilia (PWH) are lacking. The aims of this study were to analyse the prevalence of AF and risk factors for stroke using a cross-sectional pan-European design and to document current anticoagulation practice. The ADVANCE Working Group consists of members from 14 European haemophilia centres. Each centre retrieved data on their PWH with AF.
From the total of 3952 adult ifoxetine PWH, 33 had AF with a mean age of 69 years (IQR 62–76). Haemophilia was severe in seven (21%), moderate in six (18%) and mild in 20 (61%) patients. The overall AF prevalence was 0.84% and increased with age; 0.42% in patients 40–60 years and 3.4% in patients >60 years. The mean CHA2DS2-Vasc score was 1.3 (range 0–4), predominantly determined by age and hypertension. Hypertension was reported in 48% of PWH with AF. In 11 patients (33%), anticoagulation was started of whom nine aspirin and two vitamin K antagonists. Of these 11 patients, nine had mild haemophilia. Anticoagulation was given in 42% of patients with a CHA2DS2-Vasc score ≥2. During follow-up (mean 57 months), there were no thrombotic events reported, nor increases in bleeding severity.